Stock Track | NeoGenomics Plunges 6.59% Pre-Market After Reporting Q4 Net Loss

Stock Track02-17

NeoGenomics' stock plummeted 6.59% in pre-market trading on Tuesday, following the release of its fourth-quarter and full-year 2025 results.

The cancer diagnostics company reported a net loss of $10 million for the fourth quarter, despite beating adjusted earnings per share estimates. NeoGenomics posted an adjusted EPS of $0.06, surpassing the Ibes estimate of $0.04.

Investors appeared to focus on the bottom-line loss, driving the stock lower even as the company provided full-year 2026 revenue guidance that was roughly in line with analyst expectations. The mixed earnings report has left analysts conflicted about the company's near-term prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130654193?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130654193","market":"hk","top_or_hot":-1,"title":"Stock Track | NeoGenomics Plunges 6.59% Pre-Market After Reporting Q4 Net Loss","media":"Stock Track","content":"<p>NeoGenomics' stock plummeted 6.59% in pre-market trading on Tuesday, following the release of its fourth-quarter and full-year 2025 results.</p><p>The cancer diagnostics company reported a net loss of $10 million for the fourth quarter, despite beating adjusted earnings per share estimates. NeoGenomics posted an adjusted EPS of $0.06, surpassing the Ibes estimate of $0.04.</p><p>Investors appeared to focus on the bottom-line loss, driving the stock lower even as the company provided full-year 2026 revenue guidance that was roughly in line with analyst expectations. The mixed earnings report has left analysts conflicted about the company's near-term prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | NeoGenomics Plunges 6.59% Pre-Market After Reporting Q4 Net Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | NeoGenomics Plunges 6.59% Pre-Market After Reporting Q4 Net Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-17 22:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NeoGenomics' stock plummeted 6.59% in pre-market trading on Tuesday, following the release of its fourth-quarter and full-year 2025 results.</p><p>The cancer diagnostics company reported a net loss of $10 million for the fourth quarter, despite beating adjusted earnings per share estimates. NeoGenomics posted an adjusted EPS of $0.06, surpassing the Ibes estimate of $0.04.</p><p>Investors appeared to focus on the bottom-line loss, driving the stock lower even as the company provided full-year 2026 revenue guidance that was roughly in line with analyst expectations. The mixed earnings report has left analysts conflicted about the company's near-term prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEO","symbol_name":"NeoGenomics","start_time":0,"source_url":"","article_id":"1130654193","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130654193","pubTimestamp":1771338661,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"NeoGenomics' stock plummeted 6.59% in pre-market trading on Tuesday, following the release of its fourth-quarter and full-year 2025 results.The cancer diagnostics company reported a net loss of $10...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEO":"NeoGenomics"},"translate_title":"个股追踪|NeoGenomics公布Q4净亏损盘前暴跌6.59%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEO":1},"content_text":"NeoGenomics' stock plummeted 6.59% in pre-market trading on Tuesday, following the release of its fourth-quarter and full-year 2025 results.The cancer diagnostics company reported a net loss of $10 million for the fourth quarter, despite beating adjusted earnings per share estimates. NeoGenomics posted an adjusted EPS of $0.06, surpassing the Ibes estimate of $0.04.Investors appeared to focus on the bottom-line loss, driving the stock lower even as the company provided full-year 2026 revenue guidance that was roughly in line with analyst expectations. The mixed earnings report has left analysts conflicted about the company's near-term prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130654193","isCrawlerRequest":true}